BIO Announces Dr. Michael Rosenblatt, Merck Chief Medical Officer, as Keynote Speaker for the BIO Convention in China
Washington, D.C. (June 13, 2012) - The Biotechnology Industry Organization(BIO) announced today that Michael Rosenblatt, M.D., executive vice president and chief medical officer for Merck, will deliver a keynote address at the BIO Convention in China, October 24-25, 2012, in Shanghai. The event expects to bring together global biotechnology executives, pharmaceutical companies and investment firms to meet and explore business opportunities within China’s emerging biotech sector.
“Dr. Michael Rosenblatt’s unique combination of academia, industry and global public health experience makes him distinctly qualified to highlight the opportunities and challenges associated with biopharma research and development in China and the West,” said Alan Eisenberg, executive vice president of Emerging Companies and Business Development at BIO.
Dr. Rosenblatt will provide one of two keynote addresses by westerners. Governor Jon Huntsman, former U.S. Ambassador to China and Governor of Utah, will also provide a keynote address. Attendees will also hear keynote addresses from Chinese leaders, who will be announced at a later date.
Noted for his work in drug development, training of medical students, and major medical center leadership, Dr. Rosenblatt has served as dean of the Boston-based Tufts University School of Medicine; George R. Minot Professor of Medicine at Harvard Medical School; and president of Beth Israel Deaconess Medical Center (BIDMC). He was the Harvard faculty dean and senior vice president for academic programs at BIDMC. He was also director of the Harvard-MIT Division of Health Sciences and Technology. He returned to Merck in late 2009 as the company’s first chief medical officer.
“During my trips to China, I’ve been struck by the energy, power and still-growing potential of that great nation. There is enormous opportunity to improve the health of millions of people in China through novel collaborations among industry, academia, government and others committed to contributing to the success of China’s healthcare reform plan,” Dr. Rosenblatt said.
Dr. Rosenblatt is engaged in Merck efforts now underway in China, including collaborations with academic medical centers in the areas of clinical research and medical education.
The BIO Convention in Chinawill feature plenary sessions and workshops on health and regulatory issues, intellectual property, business development and vaccines, and global health. The conference will also feature company presentations, partnering meeting opportunities, and an Exhibition. The convention will include biopharmaceutical industry leaders from North America, Europe and Asia.
BIO brings to China more than 16 years of experience in organizing international conferences for the biotech industry, including the BIO International Convention, the world’s largest annual biotech conference. BIO is renowned for its successful business development, partnering and investor meetings in North America, Europe and Asia. Partnering at this conference will be powered by BIO One-on-One Partnering™, an interactive environment to intelligently search, contact and schedule private meetings with potential partners and investors.
For more information on BIO China, please visit here.